Growth Metrics

KalVista Pharmaceuticals (KALV) Revenue (2014 - 2025)

KalVista Pharmaceuticals recorded quarterly Revenue of $57.0 million in Q3 2025, up 418.18% quarter-over-quarter from $11.0 million in Q2 2025.

KalVista Pharmaceuticals' Revenue history runs 8 years deep, the most recent figure standing at $57.0 million for Q3 2025.

  • In Q3 2025, Revenue changed N/A year-over-year to $57.0 million; the TTM figure through Jul 2025 stood at $71.8 million (up 670.56% YoY), while the FY2025 annual figure was $11.0 million, down 78.0% from the prior year.
  • Revenue came in at $57.0 million for Q3 2025 at KalVista Pharmaceuticals, up from $11.0 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $57.0 million in Q3 2025 to a low of $11.0 million in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Revenue (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 306.30 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 2.99 Bn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 3.61 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 1.17 Bn
10 KalVista Pharmaceuticals 1.44 Bn 1.25 Bn 56.41 Mn 57.00 Mn

Historic Data

Download Data 🔒
DateValue
Jul 31, 2025 57.00 Mn
Apr 30, 2025 11.00 Mn
Apr 30, 2020 3.82 Mn
Jan 31, 2020 1.58 Mn
Oct 31, 2019 3.92 Mn
Jul 31, 2019 3.37 Mn
Apr 30, 2019 2.93 Mn
Jan 31, 2019 3.89 Mn
Oct 31, 2018 5.59 Mn
Jul 31, 2018 3.72 Mn
Apr 30, 2018 4.84 Mn
Jan 31, 2018 2.33 Mn
Oct 31, 2017 1.13 Mn
Jul 31, 2017 96,000.00
Apr 30, 2017 114,000.00
Jan 31, 2017 248,000.00
Oct 31, 2016 197,000.00
Jul 31, 2016 975,000.00
Mar 31, 2016 7,000.00
Dec 31, 2015 7,000.00
Sep 30, 2015 7,000.00
Jun 30, 2015 7,000.00
Mar 31, 2015 7,000.00
Dec 31, 2014 8,000.00
Sep 30, 2014 10,000.00
Jun 30, 2014 5,000.00
Mar 31, 2014 6,000.00